Academic Performance among Children with Inflammatory Bowel Disease: A Population-Based Study - 24/04/15
, Zoann Nugent, PhD 1, 2, 4, Marni Brownell, PhD 3, 5, Laura E. Targownik, MD, MSc 1, 2, Leslie L. Roos, PhD 3, 5, Charles N. Bernstein, MD 1, 2Abstract |
Objectives |
To determine grade 12 academic performance for children with inflammatory bowel disease (IBD).
Study design |
Children diagnosed with IBD at age <17 years identified from the population-based University of Manitoba IBD Epidemiology Database were matched by age-, sex-, and area of residence to 10 randomly selected controls. Grade 12 educational outcomes (scores on the provincial grade 12 language arts and mathematics standards tests, and enrollment-in-grade-12-by- age-17) were determined by linkage to the province wide Manitoba Education Database. Linear and logistic regression analysis were used to compare the educational outcomes, adjusting for socioeconomic status and comorbidities and evaluate predictors of educational outcomes among children with IBD.
Results |
Grade 12 educational outcomes among 337 children with IBD were compared with 3093 without IBD. There were no significant differences among the 2 groups in the standardized scores (language arts: P = .31; mathematics: P = .48) or enrollment-in-grade-12-by- age-17 (P = .25). Lower socioeconomic status and diagnosis with mental health problems 6 months prior to and 6 months post-IBD diagnosis were independent predictors of worse educational outcomes. There was no significant effect of age of diagnosis of IBD, type of IBD (ulcerative colitis vs Crohn's disease), use of corticosteroids or immunomodulator agents, hospitalizations, or surgery for IBD.
Conclusions |
Children with IBD on average achieve similar levels of academic achievement in grade 12 as those without IBD. This study underscores the educational impact of mental health conditions at IBD diagnosis among children.
El texto completo de este artículo está disponible en PDF.Keyword : CD, DPIN, IBD, LAI, MAI, SEFI, SES, TNF, UC, UMIBDED
Esquema
| Funded by the American College of Gastroenterology Clinical Research Award. C.B. is supported in part by the Bingham Chair in Gastroenterology; serves as a consultant to Abbvie Canada, Cubist Canada, Forest Canada, Shire Canada, Takeda Canada, and Pfizer; and has received research grants from Abbvie Canada and unrestricted educational grant from Takeda Canada, Shire Canada, and Abbvie Canada. L.T. is supported by the Canadian Institutes of Health Research New Investigator Award; has received Research Support from Abbvie Canada and Pfizer Canada (WI174703); has participated on Advisory Boards for Abbvie Canada, Takeda Canada, and Janssen Canada; and has served on Speaker's Panels for Pfizer Canada and Takeda Canada. H.S. has served as a consultant for Medial Cancer Screening Ltd., Israel. M.B. is supported by the Government of Manitoba through the Manitoba Center for Health Policy Population-Based Child Health Research Award. The other authors declare no conflicts of interest. The results and conclusions are those of the authors and no official endorsement by Manitoba Center for Health Policy or Manitoba Health is intended or should be inferred. |
Vol 166 - N° 5
P. 1128-1133 - mai 2015 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
